Company intelligence / Profile preview
Nuvalent
Cambridge, Massachusetts, United Statesnuvalent.com ↗
- Ownership
- Public · NUVL
- Employees
- ~125
- Development stage
- Phase 3
01
Overview
Nuvalent has demonstrated the ability to rationally design selective small molecule inhibitors for clinically validated kinase targets. Recent publications reinforce the potential of their lead candidate, zidesamtinib, as a novel ROS1-selective inhibitor. The company’s programs are advancing through clinical trials targeting cancers driven by specific genetic alterations and resistance mechanisms
- Therapeutic areas
- Oncology
- Modalities
- small molecules (precisely targeted kinase inhibitors)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not specified in provided sources.
Beyond the preview
Go deeper on Nuvalent.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuvalent.